{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:57:39Z","timestamp":1793977059010,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T00:00:00Z","timestamp":1503532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T00:00:00Z","timestamp":1503532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Human mesenchymal stromal cells (MSCs) have been widely investigated both for regenerative medicine and their antinflammatory\/immunomodulatory capacity. However, their ability to home pathological tissues suggested the development of strategies for using MSCs as carrier to deliver drug into tumor microenvironment. MSCs obtained from different tissues can be loaded\n                    <jats:italic>in vitro<\/jats:italic>\n                    with anti-cancer drugs by a simple procedures. In this report, we studied MSCs isolated and expanded from gingival papilla (GinPa-MSCs), by testing their ability to uptake and release three important anti-neoplastic drugs: Paclitaxel (PTX), Doxorubicin (DXR) and Gemcitabine (GCB). The efficacy of drugs releasing GinPa-MSCs was studied on a pancreatic cancer cell line and confirmed\n                    <jats:italic>in vitro<\/jats:italic>\n                    against a line of tongue squamous cell carcinoma (SCC154). Our results demonstrated that GinPa-MSCs efficiently incorporate the drugs and then released them in active form and in sufficient amount to produce a dramatic inhibition of squamous cell carcinoma growth\n                    <jats:italic>in vitro<\/jats:italic>\n                    . If compared with other MSCs sources, the collection of GinPa-MSCs is poorly invasive and cells can be easily expanded and efficiently loaded with anti cancer drugs. In particular, gemcitabine loaded GinPa-MSCs provide a good \u201ccell-mediated drug delivery system\u201d for a future potential application in the context of the oral oncology.\n                  <\/jats:p>","DOI":"10.1038\/s41598-017-09175-4","type":"journal-article","created":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T10:19:49Z","timestamp":1503051589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Drug Loaded Gingival Mesenchymal Stromal Cells (GinPa-MSCs) Inhibit In Vitro Proliferation of Oral Squamous Cell Carcinoma"],"prefix":"10.1038","volume":"7","author":[{"given":"Valentina","family":"Cocc\u00e8","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Farronato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Teresa","family":"Brini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Masia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo Bruno","family":"Giann\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Piovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Alessandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Angiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Pessina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,24]]},"reference":[{"key":"9175_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA Cancer J Clin. \n                           55, 74\u2013108 (2005).","journal-title":"CA Cancer J Clin."},{"issue":"3","key":"9175_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1543-2912(13)60091-0","volume":"1","author":"AD Gibson","year":"2004","unstructured":"Gibson, A. D., Crawford, J. & Jain, V. K. Impact of correction of anemia on clinical outcome in patients with cancer: recent data from head and neck and breast cancer trials. Support Cancer Ther. \n                           1(3), 145\u2013149 (2004).","journal-title":"Support Cancer Ther."},{"key":"9175_CR3","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1200\/JCO.2004.06.147","volume":"22","author":"EE Cohen","year":"2004","unstructured":"Cohen, E. E., Lingen, M. W. & Vokes, E. E. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol. \n                           22, 1743\u20131752 (2004).","journal-title":"J Clin Oncol."},{"issue":"10","key":"9175_CR4","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1097\/00001813-200511000-00011","volume":"16","author":"S Stier","year":"2005","unstructured":"Stier, S. et al. Gemcitabine and paclitaxel in metastatic or recurrent squamous cell carcinoma of the head and neck: a phase I-II study. Anticancer Drugs. \n                           16(10), 1115\u20131121 (2005).","journal-title":"Anticancer Drugs."},{"key":"9175_CR5","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1200\/JCO.2005.05.3348","volume":"24","author":"AD Colevas","year":"2006","unstructured":"Colevas, A. D. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. \n                           24, 2644\u20132652 (2006).","journal-title":"J Clin Oncol."},{"issue":"43","key":"9175_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001777","volume":"94","author":"Z Luo","year":"2015","unstructured":"Luo, Z. et al. A Phase II Study of Gemcitabine, Vincristine, and Cisplatin as Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma. Medicine (Baltimore). \n                           94(43), e1777 (2015).","journal-title":"Medicine (Baltimore)."},{"issue":"12","key":"9175_CR7","doi-asserted-by":"publisher","first-page":"4822","DOI":"10.1073\/pnas.0806647106","volume":"106","author":"LS Sasportas","year":"2009","unstructured":"Sasportas, L. S. et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA \n                           106(12), 4822\u20134827 (2009).","journal-title":"Proc Natl Acad Sci USA"},{"key":"9175_CR8","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.molmed.2013.08.007","volume":"19","author":"DW Stuckey","year":"2013","unstructured":"Stuckey, D. W. & Shah, K. TRAIL on trial: preclinical advances in cancer therapy. Trends. Mol. Med. \n                           19, 685\u2013694 (2013).","journal-title":"Trends. Mol. Med."},{"issue":"12","key":"9175_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028321","volume":"6","author":"A Pessina","year":"2011","unstructured":"Pessina, A. et al. Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS One. \n                           6(12), e28321 (2011).","journal-title":"PLoS One."},{"issue":"1 Suppl","key":"9175_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/03946320130260S105","volume":"26","author":"A Bonomi","year":"2013","unstructured":"Bonomi, A. et al. Adipose tissue-derived stromal cells primed in vitro with paclitaxel acquire anti-tumor activity. Int J Immunopathol Pharmacol. \n                           26(1 Suppl), 33\u201341 (2013).","journal-title":"Int J Immunopathol Pharmacol."},{"issue":"3","key":"9175_CR11","first-page":"523","volume":"13","author":"A Pessina","year":"2013","unstructured":"Pessina, A. et al. Human skin-derived fibroblasts acquire in vitro anti-tumor potential after priming with Paclitaxel. Anticancer Agents Med Chem. \n                           13(3), 523\u2013530 (2013).","journal-title":"Anticancer Agents Med Chem."},{"issue":"4","key":"9175_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/ced.12811","volume":"41","author":"V Cocc\u00e8","year":"2016","unstructured":"Cocc\u00e8, V. et al. Human skin-derived fibroblasts used as a \u2018Trojan horse\u2019 for drug delivery. Clin Exp Dermatol. \n                           41(4), 417\u2013424 (2016).","journal-title":"Clin Exp Dermatol."},{"issue":"6","key":"9175_CR13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1517\/17425247.2016.1167037","volume":"13","author":"AT Brini","year":"2016","unstructured":"Brini, A. T. et al. Cell-mediated drug delivery by gingival interdental papilla mesenchymal stromal cells (GinPa-MSCs) loaded with paclitaxel. Expert Opin Drug Deliv. \n                           13(6), 789\u2013798 (2016).","journal-title":"Expert Opin Drug Deliv."},{"issue":"4","key":"9175_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.oraloncology.2007.05.003","volume":"44","author":"CL Martin","year":"2008","unstructured":"Martin, C. L. et al. Chromosomal imbalances in oral squamous cell carcinoma: examination of 31 cell lines and review of the literature. Oral Oncol. \n                           44(4), 369\u2013382 (2008).","journal-title":"Oral Oncol."},{"key":"9175_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(88)80116-5","volume":"85","author":"JC McIntosh","year":"1988","unstructured":"McIntosh, J. C., Schoumacher, R. A. & Tiller, R. E. Pancreatic adenocarcinoma in a patient with cystic fibrosis. Am J Med. \n                           85, 592 (1988).","journal-title":"Am J Med."},{"issue":"10","key":"9175_CR16","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1073\/pnas.87.10.4012","volume":"87","author":"RA Schoumacher","year":"1990","unstructured":"Schoumacher, R. A. et al. A cystic fibrosis pancreatic adenocarcinoma cell line. Proc Natl Acad Sci USA \n                           87(10), 4012\u20134016 (1990).","journal-title":"Proc Natl Acad Sci USA"},{"key":"9175_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mossman","year":"1983","unstructured":"Mossman, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol. Methods \n                           65, 55\u201363 (1983).","journal-title":"J Immunol. Methods"},{"key":"9175_CR18","first-page":"493","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method of estimating fifty percent endpoints. Am J Hyg. \n                           27, 493\u2013497 (1938).","journal-title":"Am J Hyg."},{"issue":"12","key":"9175_CR19","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.jcyt.2015.09.005","volume":"17","author":"A Bonomi","year":"2015","unstructured":"Bonomi, A. et al. Gemcitabine-releasing mesenchymal stromal cells inhibit in vitro proliferation of human pancreatic carcinoma cells. Cytotherapy \n                           17(12), 1687\u20131695 (2015).","journal-title":"Cytotherapy"},{"key":"9175_CR20","doi-asserted-by":"crossref","unstructured":"Cocc\u00e8, V. et al. Fluorescent immortalized human adipose derived stromal cells (hASCs-TS\/GFP+) for studying cell drug delivery mediated by microvesicles. Anticancer Agents Med Chem. [Epub ahead of print] (2017).","DOI":"10.2174\/1871520617666170327113932"},{"key":"9175_CR21","first-page":"5000","volume":"9","author":"J Garcia-Manteiga","year":"2003","unstructured":"Garcia-Manteiga, J., Molina-Arcas, M., Casado, F. J., Mazo, A. & Pastor-Anglada, M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 20, 20-difluorodeoxycytidine- induced cytotoxicity. Clin Cancer Res. \n                           9, 5000\u20135008 (2003).","journal-title":"Clin Cancer Res."},{"issue":"31","key":"9175_CR22","doi-asserted-by":"publisher","first-page":"7080","DOI":"10.3748\/wjg.v22.i31.7080","volume":"22","author":"CT Hsueh","year":"2016","unstructured":"Hsueh, C. T., Selim, J. H., Tsai, J. Y. & Hsueh, C. T. Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma. World J Gastroenterol. \n                           22(31), 7080\u20137090 (2016).","journal-title":"World J Gastroenterol."},{"issue":"3","key":"9175_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1517\/14728214.2010.497754","volume":"15","author":"C Fung","year":"2010","unstructured":"Fung, C. & Grandis, J. R. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs. \n                           15(3), 355\u2013373 (2010).","journal-title":"Expert Opin Emerg Drugs."},{"issue":"2","key":"9175_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/1759-7714.12300","volume":"7","author":"Y Luo","year":"2016","unstructured":"Luo, Y., Li, J. L., Yang, L. & Zhang, W. Chemotherapy with gemcitabine plus cisplatin in patients with advanced thymic squamous cell carcinoma: Evaluation of efficacy and toxicity. Thorac Cancer. \n                           7(2), 167\u2013172 (2016).","journal-title":"Thorac Cancer."},{"issue":"2","key":"9175_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4103\/2231-0770.154195","volume":"5","author":"A Sukari","year":"2015","unstructured":"Sukari, A. et al. Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck. Avicenna J Med. \n                           5(2), 36\u201341 (2015).","journal-title":"Avicenna J Med."},{"issue":"3","key":"9175_CR26","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O\u2019Brien","year":"2004","unstructured":"O\u2019Brien, M. E. et al. CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. \n                           15(3), 440\u2013449 (2004).","journal-title":"Ann Oncol."},{"key":"9175_CR27","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3109\/02841869409121767","volume":"33","author":"P Boffetta","year":"1994","unstructured":"Boffetta, P. & Kaldor, J. M. Secondary malignancies following cancer chemotherapy. Acta Oncol. \n                           33, 591\u2013598 (1994).","journal-title":"Acta Oncol."},{"issue":"12","key":"9175_CR28","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1634\/theoncologist.2011-0216","volume":"17","author":"TL Cannon","year":"2012","unstructured":"Cannon, T. L. et al. Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer? Oncologist. \n                           17(12), 1541\u20131546 (2012).","journal-title":"Oncologist."},{"key":"9175_CR29","doi-asserted-by":"crossref","unstructured":"Pezzoli, M., Bona Galvagno, M. & Bongioannini, G. Oral squamous cell carcinoma in a patient treated with long-term pegylated liposomal doxorubicin for recurrent ovarian cancer. BMJ Case Rep. 14 (2015).","DOI":"10.1136\/bcr-2014-204056"},{"key":"9175_CR30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00001622-200405000-00005","volume":"16","author":"MK Gibson","year":"2004","unstructured":"Gibson, M. K. & Forastiere, A. A. Multidisciplinary approaches in the management of advanced head and neck tumors: State of the art. Curr Opin Oncol. \n                           16, 220\u2013224 (2004).","journal-title":"Curr Opin Oncol."},{"issue":"3","key":"9175_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.bbrc.2010.01.126","volume":"393","author":"GB Tomar","year":"2010","unstructured":"Tomar, G. B. et al. Human gingiva-derived mesenchymal stem cells are superior to bone marrow-derived mesenchymal stem cells for cell therapy in regenerative medicine. Biochem Biophys Res Commun. \n                           393(3), 377\u2013383 (2010).","journal-title":"Biochem Biophys Res Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09175-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09175-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09175-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T04:19:01Z","timestamp":1671769141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09175-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,24]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["9175"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-09175-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,24]]},"assertion":[{"value":"5 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9376"}}